Alexandria Venture Investments

Alexandria Venture Investments, LLC is a venture capital firm established in 1996 and headquartered in Pasadena, California. It specializes in seed, early-stage, and growth capital investments primarily within the healthcare sector, with a particular emphasis on biopharma, diagnostics, life sciences, agrifood technology, and technology sectors. The firm is recognized for its strategic approach, providing long-term investment capital to innovative companies that are developing transformative technologies and therapies aimed at improving human health. As a subsidiary of Alexandria Real Estate Equities, Alexandria Venture Investments leverages its deep industry expertise, extensive relationships with investors, and a world-class scientific advisory network to support and fund promising startups and growth-oriented companies in disruptive life science and technology.

Hunter Reed

Vice President

Stephen A. Richardson

Co-CEO

Past deals in Medical

Solu Therapeutics

Series A in 2025
Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating cells responsible for driving diseases. Utilizing a unique cytotoxicity-targeting chimera platform, Solu Therapeutics focuses on oncology and also addresses inflammatory and autoimmune diseases. By targeting these disease-driving cells, the company's approach seeks to assist medical professionals in reducing the risks associated with various oncological conditions, ultimately improving patient outcomes and advancing therapeutic options in the healthcare sector.

Autoimmunity BioSolutions

Seed Round in 2024
Autoimmunity BioSolutions is a biotechnology company developing innovative solutions for autoimmune diseases, with a focus on multiple sclerosis. Their core technology involves a next-generation immuno-corrective therapy, tailored to a specific genetic subgroup of autoimmune patients. This therapy aims to restore normal immune function by targeting a specific genetic variant (SNP) driving the autoimmune pathology. The company's platform enables targeted modulation of the immune system, offering potential clients a means to correct immune system dysfunction with precision therapies.

Jupiter Bioventures

Venture Round in 2024
Jupiter Bioventures is a venture builder firm dedicated to supporting early-stage therapeutic projects. The company aims to de-risk these initiatives by carefully evaluating opportunities against specific investment criteria. By providing small amounts of seed capital, Jupiter Bioventures enables founders to cultivate their projects and advance their development. Through its focused approach, the firm plays a crucial role in fostering innovation in the therapeutic sector.

CrossBridge Bio

Seed Round in 2024
CrossBridge Bio is a biotechnology company focused on developing innovative antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes proprietary linker technology and enzymatic conjugation methods to create stable and targeted ADC therapeutics. This approach aims to improve the efficacy and safety profiles of cancer therapies, offering potential advancements in the treatment landscape. By leveraging its unique dual linker payload technology, CrossBridge Bio seeks to revolutionize how cancer is treated, providing new options for patients and healthcare providers.

Archon Bio

Seed Round in 2024
Archon Bio is a biotechnology company that specializes in engineering proteins to enhance therapeutic outcomes. It focuses on creating self-assembling protein antibody nanomaterials, aiming to improve immune modulation and super agonism of the TNF receptor superfamily. By increasing the size and valency of off-the-shelf antibodies, Archon seeks to induce stronger responses, thereby advancing regenerative medicine and cancer treatment.

Leal Therapeutics

Venture Round in 2024
Leal Therapeutics is a Massachusetts-based company focused on developing innovative therapeutics for patients with significant central nervous system conditions. The company addresses urgent and unmet medical needs by providing precision medicines tailored to improve patient outcomes. Through its dedication to advancing therapeutic services, Leal Therapeutics aims to enhance the quality of care for individuals affected by challenging neurological disorders.

March Biosciences

Series A in 2024
March Biosciences is a clinical-stage biotechnology company specializing in cell therapies for hematological cancers. Its primary focus is on developing CAR-T cell therapies, with a lead asset, MB-105, targeting CD5 in refractory T-cell lymphoma and leukemia, currently in Phase 1 trials. The company's approach involves biologically informed target selection, simplified CAR-T engineering, and a streamlined manufacturing process that prioritizes cell functionality and consistency.

Judo Bio

Series A in 2024
Judo Bio is a biotechnology company focused on developing precision therapeutics that target specific cell populations to treat genetic diseases. Utilizing an innovative receptor targeting approach, Judo Bio is building a pipeline of therapies designed to benefit patients suffering from both common and rare conditions. Currently, the company is operating in stealth mode, indicating a focus on research and development without public visibility.

858 Therapeutics

Series B in 2024
858 Therapeutics is a biotechnology company dedicated to the discovery of small molecule therapeutics aimed at treating cancers and other diseases, particularly those resistant to existing therapies. The company employs innovative strategies in areas such as synthetic lethality, innate immunity, and RNA modulation to develop its therapeutic candidates. Its lead program focuses on a PARG inhibitor, which is currently in early clinical development. By leveraging its platform to investigate the role of RNA modifying proteins in disease biology, 858 Therapeutics is generating a pipeline of targeted small molecules that address critical unmet medical needs in oncology and immunology.

Radiant Biotherapeutics

Series A in 2024
Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

Bright Peak Therapeutics

Series C in 2024
Bright Peak Therapeutics is a biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company specializes in cytokine therapeutics that enable tissue and cell-specific targeting of cytokine payloads. This approach aims to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging innovative immuno-cytokines, Bright Peak seeks to provide more effective therapeutic options for complex medical conditions.

OverT Bio

Seed Round in 2024
OverT Bio is a biotechnology company focused on developing cell therapies for cancer treatment. The company specializes in identifying and creating novel genetic modifications that empower immune cells to navigate and overcome the barriers posed by tumors. By enhancing the effectiveness and durability of immunotherapies, OverT Bio aims to advance the healthcare field's ability to identify and ultimately cure cancer.

Delphia Therapeutics

Series A in 2024
Delphia Therapeutics, headquartered in Boston, USA, is a biotechnology company focused on developing innovative cancer treatments. It operates a laboratory where researchers study cancer-driving pathways to create targeted therapies. The company's approach involves selectively over-activating certain cancer-linked cell signaling pathways, making tumor cells unsustainable and enabling more effective cancer treatment for patients.

Clasp Therapeutics

Series A in 2024
Clasp Therapeutics is focused on advancing cancer treatment through its innovative immunotherapeutics platform. The company develops precision medicines designed to enhance the immune system's ability to identify and eliminate challenging tumors that possess common driver mutations, irrespective of the tumor type. By enabling the targeting of cancer-specific markers, Clasp Therapeutics aims to allow for precise and selective destruction of tumor cells, thereby improving therapeutic outcomes in the field of immuno-oncology.

Ability Biologics

Seed Round in 2023
Ability Biologics is a biotechnology company focused on developing innovative immune-modulating biotherapeutics to meet the pressing medical needs of patients suffering from cancer and autoimmune diseases. The company leverages an advanced platform that employs continuously learning artificial intelligence and a comprehensive database of antigen-antibody interactions. This technology enables the creation of potent and selective antibody therapeutics, aimed at addressing significant gaps in treatment options for these challenging health conditions. By prioritizing tailored solutions, Ability Biologics seeks to enhance patient outcomes and contribute to advancements in the field of immunotherapy.

Alto Neuroscience

Series C in 2023
Alto Neuroscience is a clinical-stage biopharmaceutical company focused on improving mental health treatment through personalized medicine. By utilizing an AI-enabled biomarker platform, Alto integrates detailed patient data regarding brain activity and behavior to develop effective therapeutics for specific populations. The company aims to transform the traditional trial-and-error approach in psychiatry by matching the appropriate treatment to individual patients, thereby enhancing the effectiveness of interventions. Alto's clinical-stage assets include various products targeting conditions such as depressive disorders and schizophrenia, identified through independent brain-based biomarkers. Through its innovative approach, Alto Neuroscience seeks to redefine psychiatric care at a critical time for mental health.

Triveni Bio

Series A in 2023
Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

DEKA Biosciences

Series B in 2023
DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company is dedicated to creating life-changing medicines with disease-specific applications that enhance patient outcomes. By leveraging improved pharmacokinetics and pharmacodynamics, DEKA Biosciences aims to deliver dual and complementary cytokines directly to affected tissues or cells. This targeted approach seeks to provide patients with curative treatment options for a range of conditions, including cancer, autoimmune disorders, and infectious diseases.

Arialys Therapeutics

Seed Round in 2023
Arialys Therapeutics is a pre-clinical stage biotechnology company that specializes in neuroscience, particularly in the development of precision medicines aimed at blocking pathogenic autoantibodies in the brain. The company investigates the role of the immune system in central nervous system (CNS) health and disease, focusing on the characterization and prevalence of pathogenic auto-antibody activity. Arialys Therapeutics aims to provide advanced therapies for various CNS disorders, including neuropsychiatric conditions linked to autoimmune diseases, thereby contributing to the healthcare industry's efforts to address complex neurological challenges.

Georgiamune

Series A in 2023
Georgiamune is an immunotherapy company dedicated to advancing oncology treatments. The firm specializes in next-generation immunotherapeutic and homeostatic therapies aimed at addressing cancer and autoimmune diseases. By focusing on innovative approaches, Georgiamune seeks to enhance patient recovery from cancer, contributing to significant breakthroughs in the field of immunotherapy.

Solu Therapeutics

Seed Round in 2023
Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating cells responsible for driving diseases. Utilizing a unique cytotoxicity-targeting chimera platform, Solu Therapeutics focuses on oncology and also addresses inflammatory and autoimmune diseases. By targeting these disease-driving cells, the company's approach seeks to assist medical professionals in reducing the risks associated with various oncological conditions, ultimately improving patient outcomes and advancing therapeutic options in the healthcare sector.

Bitterroot Bio

Series A in 2023
Bitterroot Bio is a biotechnology company focused on developing innovative immunotherapy-based treatments for cardiovascular disease. By harnessing the immune system's natural capabilities to combat illness, the company conducts research to understand the significant roles of immune cells and immune modulators in the onset and advancement of cardiovascular conditions. Through its commitment to advancing medical treatments, Bitterroot Bio aims to provide effective therapies that can transform cardiovascular disease management and improve patient outcomes.

Myeloid Therapeutics

Series A in 2023
Myeloid Therapeutics is an immunology company dedicated to harnessing myeloid cells for the treatment of cancer and other diseases. The company employs its ATAK platform technology, which focuses on reprogramming innate immune cells to enhance their ability to target and eliminate cancerous cells. This platform is designed to be versatile and scalable, allowing for the development of various treatment modalities across multiple disease areas. Currently, Myeloid Therapeutics is advancing a cell therapy program aimed at T cell lymphoma, as well as a primed monocyte approach for treating glioblastoma. Through its innovative technology, the company seeks to overcome the limitations of existing cell therapies and improve patient outcomes.

Radiant Biotherapeutics

Seed Round in 2023
Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

TORL BioTherapeutics

Series B in 2023
TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative antibody-based medicines aimed at improving outcomes for cancer patients. The company specializes in creating antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) to address oncologic diseases that exhibit significant unmet medical needs. TORL BioTherapeutics employs a strategic approach that includes target identification and early discovery work, allowing them to license promising drug programs and develop proprietary therapies with optimized characteristics. Through this pipeline, TORL BioTherapeutics is positioned to advance novel treatments that could significantly enhance patient care in oncology.

Function Oncology

Series A in 2023
Function Oncology is a precision medicine company focused on developing advanced cancer therapies through a personalized functional genomics platform powered by CRISPR technology. This innovative platform allows for the identification of therapeutic opportunities tailored to individual patients, enhancing the understanding of cancer at a patient-specific level. By leveraging cutting-edge genomic tools, Function Oncology aims to transform targeted cancer treatment and create the next generation of therapies designed to meet the unique needs of each patient.

Paratus Sciences

Series A in 2023
Paratus Sciences is a biotechnology company focused on enhancing human health and health security through the study of bat biology. By exploring the unique aspects of the bat genome, the company aims to identify and develop therapeutics for a variety of diseases. Paratus Sciences seeks to unlock the secrets of bat biology to facilitate innovative treatments, ultimately helping patients combat the health challenges they encounter.

IgGenix

Series B in 2023
IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.

Dantari

Series A in 2022
Dantari is a biotechnology company focused on developing innovative medicines for the treatment of serious diseases, including cancer and conditions affecting the central nervous system. The company utilizes a pharmaceutical platform that emphasizes the research and development of both small and large molecule therapeutics capable of crossing the blood-brain barrier. Dantari's advanced technology features a higher drug-to-antibody ratio than traditional antibody-drug conjugates (ADCs), allowing for tunable release of therapeutic payloads and the delivery of larger payloads. This approach aims to enhance efficacy and expand the therapeutic potential of its treatments, ultimately improving patient health and providing meaningful medical advancements.

Cajal Neuroscience

Series A in 2022
Cajal Neuroscience is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. By integrating human genetics, functional genomics, and advanced microscopy, the company aims to identify novel therapeutic targets. Cajal utilizes a range of cutting-edge technologies, including high-throughput functional genomics and multi-omics approaches, to screen for targets that significantly influence the progression of neurodegenerative diseases. This comprehensive methodology supports the development of precision medicine, ultimately aiding healthcare professionals in treating patients affected by these conditions.

Haystack Oncology

Series A in 2022
Haystack Oncology is an oncology company that specializes in liquid biopsy diagnostic technology aimed at improving cancer treatment strategies and patient outcomes. By utilizing advanced circulating tumor DNA detection methods, the company enhances the diagnosis of minimal residual disease, allowing for more informed therapy decision-making. Their technology focuses on identifying tumor-specific markers through blood samples, which facilitates the early detection of recurrent disease and offers increased sensitivity in monitoring residual disease post-treatment. This innovation enables healthcare teams to access cutting-edge liquid biopsy tools, thereby transforming the management of cancer and significantly improving patient care.

Capstan Therapeutics

Series A in 2022
Capstan Therapeutics is a biotechnology company focused on enhancing the therapeutic potential of in vivo RNA-based therapies. It develops proprietary targeted delivery systems, including targeted lipid nanoparticles, to improve the efficacy and control of dosage in engineered cell therapies. This innovative platform aims to address a variety of diseases, particularly in the fields of oncology, fibrosis, and inflammation, where there are significant unmet clinical needs. By advancing precision in vivo cell engineering, Capstan Therapeutics seeks to create transformative therapeutics that can offer new solutions for patients facing these challenging conditions.

Novome Biotechnologies

Series B in 2022
Novome Biotechnologies, Inc. is a biotechnology company that focuses on engineering bacteria from the human gut to develop innovative treatments for chronic diseases. Its proprietary platform, which allows for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs), is designed to provide sustained therapeutic effects. Novome's lead preclinical program targets hyperoxaluria by developing a therapeutic strain of bacteria that degrades oxalate, thereby preventing kidney stone formation. The company aims to leverage its synthetic biology tools to expand its applications into additional health conditions, enhancing its ability to deliver precise therapeutic activities through engineered gut microbiota. Founded in 2015, Novome is headquartered in South San Francisco, California.

Senda Biosciences

Series C in 2022
Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Ozette

Series A in 2022
Ozette Technologies focuses on digitizing biological data through machine learning to provide comprehensive insights into the human immune system. By leveraging a single-cell immune monitoring platform, the company enhances the discovery and annotation of immune cells, facilitating a deeper understanding of immune responses in both health and disease. Its AI-driven computational analysis technology supports scientists and healthcare providers in developing novel therapies and diagnostics, ultimately aiming to improve patient outcomes. Through its innovative approach, Ozette accelerates the advancement of therapeutic solutions by streamlining the analysis of immune data.

Cartography Biosciences

Series A in 2022
Cartography Biosciences is a biotechnology company focused on developing cancer therapies through precision medicine. The company has created a platform-based cell therapy that utilizes single-cell analysis to identify innovative CAR-T targets. This approach allows for the design of cancer immunotherapies tailored to the safest and most effective targets. By combining molecular biology and computational methods, Cartography enables clients to advance their studies in the development of these targeted treatments, aiming to improve outcomes for cancer patients.

DEM BioPharma

Series A in 2022
DEM BioPharma is an immuno-oncology company focused on developing innovative therapies aimed at eradicating cancer by targeting the innate immune system. The company has created a platform that specializes in the next generation of macrophage immunotherapies, which work by activating macrophages and immune phagocytes to effectively eliminate tumors. By researching and harnessing these immune responses, DEM BioPharma aims to provide healthcare researchers with advanced treatments that specifically target signals on both cancer cells and macrophages, offering new hope in the fight against cancer.

Dren Bio

Series B in 2022
Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

Affini-T Therapeutics

Venture Round in 2022
Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-cell therapies designed to eradicate tumors.

Eclipse BioInnovations

Series A in 2022
Eclipse Bioinnovations, founded in 2017 based on technology from the University of California, San Diego, specializes in RNA genomics. The company aims to advance RNA medicines and scientific discovery through its innovative platform technologies. Eclipse has developed eCLIP, a unique and efficient method for identifying RNA binding protein partners and gene maps. Its suite of RNA genomics technologies includes eCLIP-RBP for mapping RNA binding proteins, miR-eCLIP for studying the miR-interactome, m6A-eCLIP for RNA modifications, End-Seq for 5' and 3' mapping, and FLI-Seq for facilitating CRISPR library preparation. Eclipse offers these products as both services and kits, tailored for biopharma companies and academic researchers, enabling them to enhance their research and develop new therapies for various human diseases.

Creyon Bio

Series A in 2022
Creyon Bio is a pre-clinical stage company focused on advancing drug development through a data-driven methodology. It specializes in engineering RNA-based medicines and their components by creating proprietary datasets that inform advanced machine learning models. This innovative approach enables the rapid identification of design rules and engineering principles necessary for the development of safe and effective oligonucleotide-based medicines. By leveraging these insights, Creyon Bio aims to improve the efficiency of the drug development process, ultimately contributing to cost savings in the healthcare sector while catering to diverse patient populations.

Ambys Medicines

Series A in 2021
Ambys Medicines, Inc. is a biotechnology company based in Redwood City, California, founded in 2016. The company is dedicated to discovering and developing transformative therapies for severe liver diseases. Ambys focuses on creating innovative gene, drug, and cell therapies aimed at restoring liver function, halting the progression of liver disease, and addressing the complications associated with liver failure. By leveraging regenerative and restorative medical approaches, Ambys Medicines seeks to improve the lives of individuals affected by chronic liver conditions, providing potential relief through advanced therapeutic options.

NextVivo

Seed Round in 2021
NextVivo is a biotechnology company focused on advancing drug development through its innovative immune organoid technology platform. This platform generates human cell and antibody candidate therapies by harnessing the body's immune system. NextVivo's organoids are miniature 3D cell cultures designed to replicate the composition, structure, and function of human tissues, allowing for a realistic modeling of the humoral and cellular immune responses outside the body. This technology enables the testing of pre-clinical candidates on ex vivo human tissue models, facilitating the identification of the most effective therapies for clinical development. The company's mission is to accelerate the creation of safer and more effective treatments by utilizing immune-competent, human-derived models.

Fountain Therapeutics

Series A in 2021
Fountain Therapeutics, Inc. is a biotechnology company focused on developing treatments for age-related diseases. Founded in 2018 and based in San Francisco, California, the company aims to create a future where individuals live healthier for longer. It employs a transformative cellular model that mimics the complex characteristics of aging within a laboratory setting. By integrating this model with advanced artificial intelligence and computer vision, Fountain Therapeutics seeks to establish an innovative platform for identifying novel therapeutic targets. This approach is designed to facilitate the development of effective treatments for diseases associated with aging, ultimately aiming to reverse cellular aging and improve health outcomes.

GeneCentric Therapeutics

Series B in 2021
GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.

Parthenon Therapeutics

Series A in 2021
Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

DEKA Biosciences

Series A in 2021
DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company is dedicated to creating life-changing medicines with disease-specific applications that enhance patient outcomes. By leveraging improved pharmacokinetics and pharmacodynamics, DEKA Biosciences aims to deliver dual and complementary cytokines directly to affected tissues or cells. This targeted approach seeks to provide patients with curative treatment options for a range of conditions, including cancer, autoimmune disorders, and infectious diseases.

Immunai

Series B in 2021
Immunai Inc. is a biotechnology company that specializes in developing an artificial intelligence-based immune profiling platform aimed at enhancing drug development and improving disease detection, diagnosis, and treatment. The company utilizes single-cell genomics and machine learning algorithms to conduct high-resolution profiling of the immune system, generating valuable biological insights that facilitate research and development. Immunai's platform focuses on biomarker discovery, enabling the identification of how immune cells respond to various conditions, and supports the development of therapies for oncology and autoimmune disorders. Established in 2018 and headquartered in New York City, Immunai also maintains offices in San Francisco and Tel Aviv, collaborating with academic institutions, biopharmaceutical firms, and biotechnology companies to advance its mission of mapping the immune system and its functions.

Mozart Therapeutics

Series A in 2021
Mozart Therapeutics is a biotechnology startup dedicated to developing disease-modifying therapies for autoimmune and inflammatory diseases. The company focuses on a novel regulatory CD8 T cell network to create innovative CD8 Treg modulators aimed at treating a range of autoimmune conditions. By targeting a specific subset of T-lymphocytes, Mozart aims to restore long-term immune balance and prevent the progression of damage caused by autoreactive immune responses. Its pipeline includes first-in-class CD8 Treg modulators designed to delay the onset of autoimmune diseases and improve patient outcomes through advanced treatment options.

IpiNovyx Bio

Seed Round in 2021
IpiNovyx Bio is a biopharmaceutical company focused on creating a novel platform of immunoproteasome-modulating therapeutics aimed at improving the treatment of autoimmune and inflammatory diseases. The company's innovative approach involves developing inhibitors that selectively target the immunoproteasome, which plays a critical role in regulating specific immune cell types. By modulating these immune responses, IpiNovyx Bio seeks to enable patients to recover more effectively from their conditions and enhance their overall health.

Acrigen Biosciences

Seed Round in 2021
Acrigen Biosciences focuses on enhancing the safety and efficacy of gene editing technologies, particularly those based on the CRISPR-Cas system. Founded in 2019 and headquartered in Berkeley, California, the company develops innovative solutions that aim to produce effective in vivo drug therapies to combat various diseases. Acrigen's proprietary technologies include Acro proteins that regulate the CRISPR-Cas gene editing process and an advanced bioinformatics discovery software platform that identifies suitable CRISPR systems for human therapeutic applications. Through these advancements, Acrigen Biosciences seeks to improve the precision, efficacy, and safety of genetic therapies, ultimately contributing to the potential prevention and cure of debilitating diseases.

Kytopen

Series A in 2021
Kytopen, established in 2017 and based in Cambridge, Massachusetts, specializes in the development of a cell therapy platform. This platform facilitates the non-viral delivery of molecules into challenging-to-transfect immune cells, making the process easier, faster, and more cost-effective. The company's proprietary Flowfect™ technology combines microfluidics and automation, enabling researchers to explore new biological discoveries and develop more affordable cell and gene therapies.

ROME Therapeutics

Series B in 2021
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.

Disc Medicine

Series B in 2021
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Asher Bio

Series B in 2021
Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Humacyte

Post in 2021
Humacyte, Inc. is a medical research and development company based in Morrisville, North Carolina, focused on creating and commercializing human tissue-based products for regenerative medicine and vascular surgery. The company specializes in designing acellular extracellular matrices, which are crafted in vitro from banked vascular smooth muscle cells and decellularized to prevent rejection. These products serve as tissue-engineered grafts for patients requiring vascular repair or replacement. Humacyte's innovative approach aims to provide universally implantable bioengineered human tissues and organs, addressing various diseases, injuries, and chronic conditions while enhancing patient care and transforming medical practices. Founded in 2004, the company is committed to advancing solutions for vascular diseases and the replacement of anatomical conduits.

Thryv Therapeutics

Series A in 2021
Thryv Therapeutics is a precision medicine company focused on developing innovative therapies for Long QT Syndrome and various arrhythmias. The company employs a precision medicine approach to address both genetic and drug-induced long QT syndrome, atrial fibrillation, and treatment-resistant cancers. Thryv Therapeutics is dedicated to creating potent and selective inhibitors of Serum Glucocorticoid Inducible Kinase, aiming to reduce the risk of sudden cardiac death and enhance the quality of life for affected patients. Through its targeted therapeutic development, the company seeks to provide effective solutions for serious cardiovascular and oncological conditions.

IgGenix

Series A in 2021
IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.

Wugen

Series B in 2021
Wugen is focused on developing off-the-shelf cellular therapies for cancer, particularly utilizing natural killer (NK) cells and CAR-T cell therapies. The company enhances NK cells obtained from healthy donors to improve their ability to target and eliminate cancer cells. Wugen's innovative approach includes a proprietary platform that leverages advanced genomic engineering to create next-generation memory NK cell therapies. These therapies specifically aim to address various types of malignancies, including solid tumors, acute myeloid leukemia, and T-cell malignancies, thereby providing new treatment options for patients facing life-threatening cancers.

Cyrus Biotechnology

Venture Round in 2021
Cyrus Biotechnology, Inc. is a Seattle-based company that specializes in developing advanced software for protein structure prediction and design. Founded in 2014, it offers several key products, including Rosetta, a tool designed to create biologically active proteins for various medical applications such as treating brain cancer and addressing Celiac Disease. The company also provides Cyrus Bench, an enterprise version of Rosetta that includes a comprehensive suite of bio-molecular computation tools. Additionally, Cyrus Biotechnology offers specialized services like Cyrus CryoEM, which focuses on structure refinement and model building for complex biomolecular structures. Its innovative software solutions cater to pharmaceutical companies, biotech firms, and startups engaged in discovering therapeutics and developing novel consumer products.

Neurona Therapeutics

Venture Round in 2021
Neurona Therapeutics Inc. is a biotechnology company based in South San Francisco, California, that specializes in developing cell-based therapies for neurological disorders. Founded by neuroscientists and stem cell pioneers at The University of California, San Francisco, the company focuses on creating therapeutic compositions of specific types of neurons for targeted delivery into the injured nervous system. Drawing on nearly two decades of research, Neurona seeks to harness particular subpopulations of neurons capable of integrating and repairing dysregulated neural circuits. With a dedicated team of scientists and advisors, the company aims to accelerate the development of breakthrough treatments for patients suffering from significant unmet medical needs in the realm of chronic neurological diseases.

Mnemo Therapeutics

Series A in 2021
Mnemo Therapeutics is a biotechnology firm focused on developing immune-based therapies, particularly cell therapies, aimed at treating solid tumors and blood cancers. The company utilizes its EnfiniT platform, a drug discovery engine that harnesses a unique class of antigens and various technologies to target tumorous epitopes prevalent in multiple cancer types. By leveraging epigenetic variation and CAR-T precision genetic engineering, Mnemo Therapeutics strives to create accessible allogeneic treatments that offer effective solutions for patients facing these challenging diseases.

Senda Biosciences

Series B in 2021
Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Bright Peak Therapeutics

Series B in 2021
Bright Peak Therapeutics is a biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company specializes in cytokine therapeutics that enable tissue and cell-specific targeting of cytokine payloads. This approach aims to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging innovative immuno-cytokines, Bright Peak seeks to provide more effective therapeutic options for complex medical conditions.

miRecule

Venture Round in 2021
miRecule, Inc. is a biotechnology company based in Gaithersburg, Maryland, established in 2016. The company specializes in developing a microRNA-based drug discovery platform, DREAmiR, aimed at addressing challenges in cancer therapy and muscular dystrophy. This innovative platform leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. miRecule formulates RNA therapeutics that can directly target and correct these genetic issues. The platform integrates genomic sequencing, expression, and prognostic data from numerous cancer patients with high throughput screening of microRNA candidates for replacement therapy. miRecule is focused on creating highly tailored therapeutics, with lead programs targeting Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy, ultimately striving to improve the quality of life for patients suffering from debilitating conditions.

Soteria Biotherapeutics

Series A in 2021
Soteria Biotherapeutics, Inc., founded in 2018 and based in San Francisco, California, focuses on developing innovative immunotherapies for cancer treatment. The company is creating a new generation of conditionally active bispecific T-cell engaging antibodies specifically aimed at treating solid tumors. Utilizing its advanced T-LITE™ platform, Soteria enables small molecule-dependent activation of these bispecific antibody therapies, which facilitates safer and more effective treatment options. This approach allows for pulsatile activity, resulting in reduced side effects and the potential for higher dosing, thereby improving the overall therapeutic experience for patients.

Marvin Behavioral Health

Seed Round in 2021
Marvin is a virtual care platform that provides teletherapy and behavioral health services to healthcare workers. It works with hospitals and other healthcare organizations to provide care for their employees, providing teletherapy, meditations, and community programming specifically oriented towards their needs. The company was founded in 2020 and is based in Marina del Rey, California.

Alloy Therapeutics

Series C in 2021
Alloy Therapeutics is a biotechnology company based in Waltham, Massachusetts, founded in 2017. The company focuses on democratizing access to essential drug discovery platforms and services, primarily through its Alloy-Gx platform. This innovative platform features a royalty-free suite of immunocompetent transgenic mice that facilitate in vivo human antibody discovery. Alloy Therapeutics has developed humanized transgenic antibody discovery technology, which offers broad, non-exclusive access to drug discovery tools, allowing scientists to engage in their antibody projects more efficiently and effectively. The company's mission is to enhance the drug discovery process by providing accessible and advanced resources for researchers in the field.

SeQure DX

Venture Round in 2021
SeQure Dx specializes in providing safety data related to CRISPR gene editing therapies, focusing on both on-target and off-target effects. The company develops genomics diagnostic technologies that facilitate target profiling for gene editing, supporting the discovery, clinical development, and diagnostic processes. Its core technologies are designed to identify potential off-target sites prior to the initiation of therapy, ensuring comprehensive confirmation of actual genetic edits. This capability empowers gene editing therapeutics developers, physicians, and patients by enhancing the safety and efficacy of gene editing treatments.

Ensoma

Series A in 2021
Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Vera Therapeutics

Series C in 2021
Vera Therapeutics, a biotechnology company based in South San Francisco, California, specializes in developing innovative biologic therapeutics aimed at treating serious immunological diseases and genetic disorders. Founded in 2016 and renamed in March 2020, the company's research focuses on transformative treatments that can significantly improve patient outcomes. One of its key product candidates is atacicept, a fusion protein designed for self-administration via a weekly subcutaneous injection. Atacicept works by inhibiting both B lymphocyte stimulator and a proliferation-inducing ligand, which are involved in the production of autoantibodies that contribute to various autoimmune diseases. Additionally, Vera Therapeutics is exploring gene-editing technologies that hold the potential to address conditions such as sickle cell disease and cystic fibrosis.

Blacksmith Medicines

Seed Round in 2021
Blacksmith Medicines is focused on developing innovative therapies that target metal-dependent enzymes, known as metalloenzymes, which play a crucial role in human physiology. With over 30% of known enzymes classified as metalloenzymes, they encompass all major enzyme classes, including oxidoreductases, transferases, and hydrolases. Blacksmith Medicines utilizes a specialized platform that combines a curated library of metal-binding pharmacophores with advanced computational modeling techniques. This approach allows for the rapid and systematic design of small molecule inhibitors that specifically interact with key metal ions within the enzyme's active site. The company's efforts are particularly directed towards creating medicines for immuno-oncology and inflammatory diseases, offering the potential for more effective and selective therapeutic options.

Myeloid Therapeutics

Series A in 2021
Myeloid Therapeutics is an immunology company dedicated to harnessing myeloid cells for the treatment of cancer and other diseases. The company employs its ATAK platform technology, which focuses on reprogramming innate immune cells to enhance their ability to target and eliminate cancerous cells. This platform is designed to be versatile and scalable, allowing for the development of various treatment modalities across multiple disease areas. Currently, Myeloid Therapeutics is advancing a cell therapy program aimed at T cell lymphoma, as well as a primed monocyte approach for treating glioblastoma. Through its innovative technology, the company seeks to overcome the limitations of existing cell therapies and improve patient outcomes.

Encodia

Series C in 2020
Encodia, Inc., founded in 2015 and headquartered in San Diego, California, specializes in proteomics research and the development of innovative protein analysis technology. The company offers a platform that utilizes reverse-translation technology to convert peptide sequence information into DNA libraries, facilitating scalable and efficient protein sequencing. This capability enables researchers to analyze protein samples comprehensively, thereby advancing the field of personalized medicine. By democratizing access to detailed information on cellular processes, Encodia aims to accelerate the discovery of novel approaches to addressing challenging diseases.

Neurogene

Series B in 2020
Neurogene Inc., established in 2018 and headquartered in New York, specializes in developing genetic medicines for treating neurological disorders. The company focuses on utilizing adeno-associated virus (AAV) vectors to deliver therapeutic genes for conditions such as Charcot-Marie Tooth disease type 4J (CMT4J), Aspartylglucosaminuria (AGU), and an undisclosed Lysosomal Storage Disease (LSD). Neurogene aims to provide effective treatment options where none currently exist, aiming to improve the quality of life for patients and families affected by these rare neurological disorders.

Faze Medicines

Series A in 2020
Faze Medicines is a biotechnology company founded in 2020 and located in Cambridge, Massachusetts. The company focuses on developing small molecule drugs that target the underlying mechanisms of disease pathology, with initial therapeutic efforts directed towards conditions such as amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). Faze Medicines employs advanced screening and proteomics techniques to explore biomolecular condensate interaction networks, which aids in the identification and development of novel therapeutics. Through its innovative approach, Faze aims to provide effective treatments for patients suffering from these challenging diseases.

Vigil Neuro

Series A in 2020
Vigil Neuroscience Inc. is a therapeutics company focused on microglia, the brain's immune sentinel cells, to address both rare and common neurodegenerative diseases. The company aims to restore the vigilance of microglia to improve patient outcomes. Vigil is advancing its lead candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies and is also developing an orally available small molecule TREM2 agonist, VG-3927, which is positioned to enter Investigational New Drug (IND) application. Additionally, Vigil is conducting the IGNITE trial, a Phase 2 proof-of-concept study that represents the first interventional trial for patients with adult-onset leukodystrophy. By leveraging modern neuroscience and various therapeutic modalities, Vigil seeks to deliver precision therapies that enhance the lives of patients and their families while expanding its pipeline and supporting the understanding of microglia biology as a critical therapeutic target.

Dren Bio

Series A in 2020
Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

Sonoma Biotherapeutics

Series A in 2020
Sonoma Biotherapeutics develops adoptive Treg cell therapies aimed at treating autoimmune and degenerative diseases. The company employs advanced genome editing and target-specific cell therapy to create therapeutic solutions that promote self-tolerance and mitigate harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded in 2019 and headquartered in South San Francisco, California, with an additional office in Seattle, Washington, Sonoma Biotherapeutics combines expertise in Treg biology and proprietary methodologies to advance its therapeutic platform, focusing on developing disease-modifying and potentially curative treatments.

Korro Bio

Series A in 2020
Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Vesigen Therapeutics

Series A in 2020
Vesigen Therapeutics, established in 2020 and based in Cambridge, Massachusetts, specializes in developing innovative therapeutic products. The company's core technology, ARMMs (ARRDC1 Mediated Microvesicles), facilitates the delivery of various payloads such as RNAs, proteins, and gene-editing complexes directly into the cytoplasm of target cells. This approach overcomes intracellular delivery barriers, expanding the scope of treatable conditions and enabling the development of novel therapies for unmet medical needs.

Frequency Therapeutics

Post in 2020
Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, that aims to repair or reverse damage from various degenerative diseases by utilizing the body’s own biological mechanisms. The company employs a Progenitor Cell Activation approach, which involves the use of small molecules to activate progenitor cells and promote the regeneration of functional tissue. Its leading product candidate, FX-322, is currently undergoing phase 2a clinical trials to address the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is also exploring treatments for a range of other conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. The company has established a collaboration with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics focuses on disease modification without the complexities associated with genetic engineering.

Vor Biopharma

Series B in 2020
Vor Biopharma, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing engineered hematopoietic stem cell (eHSC) therapies for cancer treatment. The company's lead product candidate, VOR33, is designed specifically for the treatment of acute myeloid leukemia (AML) and is currently in preclinical development. VOR33 eHSCs are engineered to lack CD33, a protein commonly expressed by AML cells, allowing for selective targeting of the cancer without harming normal cells. This innovative approach seeks to minimize the toxicities associated with traditional immunotherapies, which often affect both cancerous and healthy tissues. By protecting healthy stem cells from depletion while generating functional immune cells, Vor Biopharma aims to enhance therapeutic outcomes for patients with hematological malignancies.

Autobahn Therapeutics

Series B in 2020
Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Since its incorporation in 2017, Autobahn has aimed to address significant unmet needs in neuropsychiatry and neuroimmunology through its innovative brain-targeting chemistry platform. The company's leading candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential treatment for multiple sclerosis and adrenomyeloneuropathy, as well as an adjunctive therapy for major depressive disorder and bipolar disorder depression. Autobahn Therapeutics emphasizes precision tuning of CNS exposure, targeting validated clinical and biological markers to enhance therapeutic opportunities and patient outcomes.

MoMa Therapeutics

Series A in 2020
MOMA Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2019. The company focuses on discovering precision medicines by targeting molecular machines that are fundamental to human disease. MOMA Therapeutics utilizes a unique platform that leverages the common features of the ATPase target class, which includes significant conformational changes and energy-driven mechanics. By combining these insights with advancements in structural biology and small-molecule drug discovery, MOMA Therapeutics aims to develop drugs targeting previously challenging enzymes, contributing to the next generation of targeted therapies. The company was formerly known as ATPases NewCo, Inc. before rebranding in March 2020.

Affinia Therapeutics

Series A in 2020
Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Redpin Therapeutics

Series A in 2020
Redpin Therapeutics is a preclinical stage gene therapy company based in New York, founded in 2017. The company specializes in developing a proprietary chemogenetics platform designed to create targeted cell therapies for intractable diseases of the nervous system. Its innovative approach combines principles from synthetic biology, gene therapy, and conventional pharmacotherapy, utilizing ion channels as neuromodulation tools. This enables selective activation or inhibition of disease-causing neurons, allowing for precise regulation of dysfunctional neuronal circuits while sparing healthy cells. Through its research and development efforts, Redpin Therapeutics aims to provide new treatment options for challenging neurological conditions.

Silverback Therapeutics

Series B in 2020
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.

Kallyope

Series C in 2020
Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Novome Biotechnologies

Series A in 2020
Novome Biotechnologies, Inc. is a biotechnology company that focuses on engineering bacteria from the human gut to develop innovative treatments for chronic diseases. Its proprietary platform, which allows for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs), is designed to provide sustained therapeutic effects. Novome's lead preclinical program targets hyperoxaluria by developing a therapeutic strain of bacteria that degrades oxalate, thereby preventing kidney stone formation. The company aims to leverage its synthetic biology tools to expand its applications into additional health conditions, enhancing its ability to deliver precise therapeutic activities through engineered gut microbiota. Founded in 2015, Novome is headquartered in South San Francisco, California.

Triplet Therapeutics

Series A in 2019
Triplet Therapeutics, Inc. is focused on developing innovative therapies for repeat expansion disorders, which include conditions such as Huntington’s disease, myotonic dystrophy, and spinocerebellar ataxias. Founded in 2018 and based in Cambridge, Massachusetts, the company aims to address these disorders at their source by utilizing a unique approach that involves targeting the DNA Damage Response pathway through a single oligonucleotide. This biotherapeutic technology is designed to provide a comprehensive treatment solution for multiple repeat expansion disorders, enabling healthcare professionals to better manage these complex conditions.

Aspen Neuroscience

Seed Round in 2019
Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.

Jasper Therapeutics

Series A in 2019
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, focused on developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. The company aims to create safer conditioning agents that enable broader use of curative therapies, particularly through its novel engineered hematopoietic stem cells platform. Its lead compound, JSP191, is a humanized monoclonal antibody currently in clinical development. This agent functions as a conditioning treatment by targeting and clearing hematopoietic stem cells from bone marrow, facilitating successful stem cell transplants. By addressing the limitations of transplant grafts, Jasper Therapeutics seeks to increase the number of patients who can benefit from both allogeneic and autologous gene-edited hematopoietic stem cell therapies.

ImCheck Therapeutics

Series B in 2019
ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Immunitas Therapeutics

Series A in 2019
Immunitas Therapeutics, Inc. is focused on developing targeted therapies for cancer patients through innovative single-cell analyses. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes a single-cell sequencing platform to explore the biology of immune cells within human tumors. This approach allows Immunitas to identify novel drug targets rooted in human biology and create key biomarkers that assist in selecting patients who may benefit from their therapies. By translating laboratory findings into clinical applications, Immunitas aims to address longstanding challenges in oncology and improve treatment options for complex cancers. The company is advancing multiple programs toward early human studies, leveraging expertise in antibody discovery and engineering to develop effective treatments.

Genetron Health

Series D in 2019
Genetron Health is a leading precision medicine company specializing in oncology, with a strong focus on cancer molecular profiling. The company leverages advanced technologies in molecular biology and data science to enhance cancer treatment. Genetron Health offers comprehensive health management products covering all aspects of full-cycle cancer clinical treatment, including risk assessment, early screening, molecular pathology diagnosis, medication guidance, and prognosis monitoring. They provide reliable molecular clinical services and professional cancer genetic risk assessments for patients and high-risk individuals. With global genomics sequencing and bioinformatics platforms, research and development centers in North Carolina and Beijing, and clinical laboratories across major Chinese cities, Genetron Health aims to expand its sales network throughout China. The company is dedicated to serving both Chinese and global cancer patients with its expertise in cancer genomics and efficient clinical translation.

miRecule

Venture Round in 2019
miRecule, Inc. is a biotechnology company based in Gaithersburg, Maryland, established in 2016. The company specializes in developing a microRNA-based drug discovery platform, DREAmiR, aimed at addressing challenges in cancer therapy and muscular dystrophy. This innovative platform leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. miRecule formulates RNA therapeutics that can directly target and correct these genetic issues. The platform integrates genomic sequencing, expression, and prognostic data from numerous cancer patients with high throughput screening of microRNA candidates for replacement therapy. miRecule is focused on creating highly tailored therapeutics, with lead programs targeting Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy, ultimately striving to improve the quality of life for patients suffering from debilitating conditions.

Verseau Therapeutics

Venture Round in 2019
Verseau Therapeutics, Inc. is focused on developing macrophage checkpoint modulators aimed at treating patients with cancer, as well as immune and inflammatory diseases. Founded in 2017 and based in Lexington, Massachusetts, the company is creating a new class of therapeutics that target macrophages, which are crucial cells in the immune system. By shifting these cells between immune activators and silencers, Verseau's therapies aim to enhance the body's ability to mount an effective immune response against tumors. This innovative approach seeks to improve the efficacy of existing immunotherapies, offering new hope for patients facing challenging health conditions.

Variant Bio

Series A in 2019
Variant Bio Inc. is a biotechnology company based in Seattle, Washington, that focuses on developing therapeutics through the study of human genetic diversity. Founded in 2018, the company identifies individuals and populations that exhibit extreme traits of medical significance, utilizing advanced sequencing technologies and analytic methods to uncover the genes and pathways associated with these traits. By leveraging insights from genetic research, Variant Bio aims to discover new therapeutic targets for conditions such as neurodegenerative, autoimmune, and cardiometabolic diseases. The company's innovative approach combines statistical genetics and machine learning, enhancing the potential for genomic drug discovery to address unmet medical needs.

Boundless Bio

Series A in 2019
Boundless Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of aggressive cancers linked to extrachromosomal DNA (ecDNA). Founded in 2018 and based in La Jolla, California, the company aims to address the significant unmet medical needs of patients with oncogene amplified tumors, which affect over 14% of cancer patients. By targeting ecDNA, a key factor in oncogene amplification, Boundless Bio seeks to provide transformative treatments for previously difficult-to-treat cancers. One of its leading candidates, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), designed to manage the replication and transcription of ecDNA in cancer cells.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.